1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The Coronavirus (COVID-19) company impact report analyses how the pandemic will impact Gilead Science Inc. performance.
Historically, Gilead Focused on Small Molecules for Anti-Viral Therapies.
Gilead’s Pipeline is Most Active in Early Stages of Drug Development.
Remdesivir Is the Main Focus of Attention Against COVID-19.
Gilead Acquires Forty Seven Inc. as a Continuation of Strategy to Diversify Pipeline Portfolio into Oncology.
Scope
- This PowerPoint based report gives an important expert analysis on how COVID-19 will affect Gilead Science Incorporated. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.
Reasons to Buy
- An overview of how Gilead Sciences Inc. will be affected by the COVID-19 pandemic.
Table of Contents
1 Executive Summary
2 Company Overview
3 Regional Breakout
4 Reaction to COVID-19
Companies Mentioned
A selection of companies mentioned in this report includes:
- Gilead Sciences Inc.
